- Norgine B.V. a European specialist pharmaceutical company announced today the visit of Olivier Marleix, Member of the French Assemblée Nationale Eure-et-Loir, Wassim Kamel, Sub-Prefect of Dreux and Gérard Hamel, Mayor of Dreux to celebrate investment at its manufacturing site in Dreux, France.
Since 2015, the company has invested a total of EUR 8 million in its manufacturing and quality capabilities at the Dreux facility. This includes new technology to produce MOVICOL® Ready to Take and additional packaging facilities for LYMPHOSEEK® and DANTRIUM® IV.
Norgine employs over 1,000 personnel in Europe and Australia - with over 200 employees in France, located in Dreux and Rueil Malmaison:
Peter Stein, CEO at Norgine said: "Part of Norgine's strength as a partner lies in its high quality manufacturing and distribution facilities in Hengoed, Wales and Dreux, France. These help to enable Norgine to integrate and launch new innovative products which deliver value to healthcare professionals and improve patients' lives."
Access the full press release on http://www.norgine.com /media
Media Contact: Isabelle Jouin, T: +44-(0)-189-582-6237
Follow us @norgine https://www.linkedin.com/company/norgine/
di Marcello Veneziani
di Carlantonio Solimene
di Carlo Antini
di Luigi Salomone
di Luigi Bisignani
Sede legale: Piazza Colonna, 366 - 00187 Roma CF e P. Iva e Iscriz. Registro Imprese Roma: 13486391009 REA Roma n° 1450962 Cap. Sociale € 1.000.000 i.v.
© Copyright IlTempo. Srl- ISSN (sito web): 1721-4084
Powered by Miles 33